Singapore markets close in 5 hours 43 minutes
Straits Times Index
3,299.23 +6.54 (+0.20%) Nikkei
38,299.71 +25.66 (+0.07%) Hang Seng
18,150.33 +387.30 (+2.18%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,400.65 -2,585.97 (-4.31%) CMC Crypto 200
1,259.45 -79.62 (-5.95%)
ABT Jun 2024 105.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 12:02PM EDT. Market open.
| Previous close | 4.0000 |
| Open | 4.1100 |
| Bid | 4.0000 |
| Ask | 4.1000 |
| Strike | 105.00 |
| Expiry date | 2024-06-21 |
| Day's range | 4.0300 - 4.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | 5.94k |
ZacksIs Trending Stock Abbott Laboratories (ABT) a Buy Now?
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
ZacksPBH vs. ABT: Which Stock Is the Better Value Option?
PBH vs. ABT: Which Stock Is the Better Value Option?
PR NewswireAbbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
© 2024 Yahoo. All rights reserved.